Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;15(3):217-33.
doi: 10.1007/s40272-013-0024-6.

Safety and pharmacokinetics of atypical antipsychotics in children and adolescents

Affiliations
Review

Safety and pharmacokinetics of atypical antipsychotics in children and adolescents

Silvio Caccia. Paediatr Drugs. 2013 Jun.

Abstract

Pediatric behavioral and affective disorders often require antipsychotic therapy, in combination with psychotherapeutic interventions, for their treatment and stabilization. Although pharmacotherapy can include either typical or atypical antipsychotics, the latter are generally preferred because of their apparently lower risk of adverse effects. Recent controlled trials have demonstrated the efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia and children or adolescent bipolar mania, or to treat severe aggression and self-injury in the context of autism in children and adolescents. Although few studies have systematically monitored their short- and, more importantly, long-term safety, current evidence indicates that sedation, hyperprolactinemia, and metabolic abnormalities such as excess weight gain, diabetes, and related cardiovascular effects were clinically relevant adverse effects in young patients, with the individual agents differing in their propensity to induce these effects. When prescribing antipsychotics for children and adolescents, physicians should therefore be aware of the specific adverse effect profiles and patients should be closely monitored for the short- and long-term development of adverse events. In pediatric patients, the starting dose, titration plan, and maintenance dose of antipsychotics must be based on their pharmacokinetics and metabolism, as in adults. Because there are significant individual differences in drug and active metabolite(s) pharmacokinetics and metabolism, which may be further affected by a number of confounding factors (including demographic variables, phenotype and drug interactions), therapeutic drug monitoring may be a valid tool for individualizing dosage, but its interpretation should also take account of changes in pharmacodynamic sensitivity with the development during childhood and adolescence.

PubMed Disclaimer

References

    1. Am J Psychiatry. 2008 Nov;165(11):1420-31 - PubMed
    1. Lancet. 2008 Mar 29;371(9618):1085-97 - PubMed
    1. Pediatr Clin North Am. 2011 Feb;58(1):173-87, xii - PubMed
    1. Psychiatry Res. 2011 Oct 30;189(3):349-56 - PubMed
    1. J Clin Psychiatry. 2002;63 Suppl 13:27-31 - PubMed

Substances

LinkOut - more resources